Published in Invest New Drugs on April 06, 2010
The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol (2011) 1.55
Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules. Br J Cancer (2012) 0.84
Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status. Oncotarget (2015) 0.80
A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer. Invest New Drugs (2013) 0.80
A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol (2014) 0.75
A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma. Oncotarget (2016) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Optimal two-stage designs for phase II clinical trials. Control Clin Trials (1989) 21.03
National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst (2003) 4.81
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res (2009) 3.61
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res (2006) 3.12
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol (2009) 2.88
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol (2006) 2.32
PKC at a glance. J Cell Sci (2004) 2.30
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol (2007) 1.63
The case for secondary hormonal therapies in the chemotherapy age. J Urol (2006) 1.43
Exploitation of protein kinase C: a useful target for cancer therapy. Cancer Treat Rev (2008) 1.21
Staurosporine analogues - pharmacological toys or useful antitumour agents? Crit Rev Oncol Hematol (2000) 1.09
Expression of protein kinase C isoenzymes in benign hyperplasia and carcinoma of prostate. Oncol Rep (2004) 1.09
The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs (2007) 0.99
Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Mol Pathol (1997) 0.97
Protein kinase C targeting in antineoplastic treatment strategies. Invest New Drugs (1999) 0.94
Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer. Urol Oncol (2008) 0.82
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol (2012) 7.16
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol (2011) 5.95
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2007) 5.10
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol (2006) 3.81
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst (2006) 3.63
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol (2011) 3.59
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol (2007) 3.26
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol (2014) 3.16
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer (2013) 2.61
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J Clin Oncol (2007) 2.53
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol (2011) 2.13
American society of clinical oncology policy statement: disparities in cancer care. J Clin Oncol (2009) 2.12
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol (2008) 2.03
Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. Cancer (2007) 2.02
NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw (2009) 1.97
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol (2011) 1.92
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 1.92
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.84
Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney are the same disease entity: molecular and histologic evidence. Am J Surg Pathol (2009) 1.84
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood (2008) 1.81
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol (2011) 1.80
Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer (2010) 1.77
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol (2012) 1.76
Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer (2008) 1.73
Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer (2003) 1.70
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer (2009) 1.70
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2008) 1.69
The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol (2012) 1.65
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
Modelling the random effects covariance matrix in longitudinal data. Stat Med (2003) 1.61
A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer (2009) 1.59
Identifying rodent hantavirus reservoirs, Brazil. Emerg Infect Dis (2004) 1.58
Innate immune response to encephalomyocarditis virus infection mediated by CD1d. Immunology (2003) 1.57
Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. J Urol (2012) 1.56
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2009) 1.53
Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol (2002) 1.52
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol (2011) 1.51
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia (2007) 1.50
The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. J Oncol Pract (2013) 1.48
Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health (2007) 1.45
Prostate cancer: what did we learn from the 2012 Annual Scientific Meeting of ASCO? Oncology (Williston Park) (2012) 1.43
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. J Urol (2007) 1.42
Knowledge Translation of the Gross Motor Function Classification System Among Pediatric Physical Therapists. Pediatr Phys Ther (2015) 1.38
Couples' experiences with prostate cancer: focus group research. Oncol Nurs Forum (2002) 1.37
An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res (2009) 1.36
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol (2011) 1.33
Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol (2010) 1.33
Prostate cancer, version 1.2014. J Natl Compr Canc Netw (2013) 1.32
Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer (2003) 1.31
Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregivers. Psychooncology (2012) 1.29
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys (2005) 1.23
Hantavirus pulmonary syndrome in northwestern Argentina: circulation of Laguna Negra virus associated with Calomys callosus. Am J Trop Med Hyg (2004) 1.22
T2 measurement of J-coupled metabolites in the human brain at 3T. NMR Biomed (2011) 1.19
Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma. Clin Genitourin Cancer (2007) 1.19
Survival disparities by Medicaid status: an analysis of 8 cancers. Cancer (2011) 1.18
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer (2009) 1.17
Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era. PLoS One (2013) 1.17
Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol (2005) 1.17
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res (2012) 1.13
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.13
The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol (2009) 1.13
NCCN Task Force Report: Bone Health In Cancer Care. J Natl Compr Canc Netw (2013) 1.12
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol (2005) 1.12
In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res (2007) 1.08
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer (2006) 1.08
Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther (2009) 1.07
Towards an understanding of the role of Clostridium perfringens toxins in human and animal disease. Future Microbiol (2014) 1.07
Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res (2007) 1.06
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology (2011) 1.06